{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:10:23Z","timestamp":1778285423431,"version":"3.51.4"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015542","name":"GlaxoSmithKline Japan","doi-asserted-by":"publisher","award":["214644"],"award-info":[{"award-number":["214644"]}],"id":[{"id":"10.13039\/100015542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Anemia is associated with increased morbidity, mortality, healthcare resource utilization, and costs in myelofibrosis. This longitudinal, retrospective, and descriptive cohort study used a Japanese health administrative database (Medical Data Vision) to examine treatment patterns, transfusion burden, healthcare resource utilization, and costs in patients with myelofibrosis and a subset treated with a Janus kinase inhibitor. Ruxolitinib (a Janus kinase inhibitor) was the first targeted therapy for myelofibrosis in Japan (2014). Patients were identified from April 1, 2015 to June 30, 2022. In the overall myelofibrosis cohort, myelofibrosis diagnosis was the index date; in the Janus kinase inhibitor-treated subgroup, the first date of Janus kinase inhibitor use was the index date. Of the 836 patients with myelofibrosis, median age: 73 years at or before index; female: 38.0%; median follow-up: 576 days; anemia: 59.9%; thrombocytopenia: 18.7%. At index, 37.9%, 6.6%, and 55.5% of patients were transfusion-dependent, -requiring, and -independent, respectively. Median overall survival from myelofibrosis diagnosis was 83.3 months from the index date. Of 281 patients who received a Janus kinase inhibitor, median age: 74 years at or before index; female: 39.5%; median follow-up: 592 days; anemia: 66.9%; thrombocytopenia: 22.8%. All patients who received a JAK inhibitor were treated with ruxolitinib; mean dose was 15.6 mg\/day and median duration of treatment was 14 months. The proportion of patients who were transfusion-dependent, -requiring, and -independent in this subgroup was 47.0%, 9.3%, and 43.8%, respectively. Median overall survival from myelofibrosis diagnosis was 53.9 months from first Janus kinase inhibitor administration. This real-world study showed the clinical characteristics and outcomes of Japanese patients with myelofibrosis.<\/jats:p>","DOI":"10.1371\/journal.pone.0348598","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:12:12Z","timestamp":1778281932000},"page":"e0348598","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world patient characteristics and clinical outcomes in patients with myelofibrosis in Japan"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1853-974X","authenticated-orcid":true,"given":"Yusuke","family":"Yasutomi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9909-5649","authenticated-orcid":true,"given":"Seok-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"McGuiness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Slowley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"pone.0348598.ref001","first-page":"89","article-title":"Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes","volume":"7","author":"TI Mughal","year":"2014","journal-title":"Int J Gen Med"},{"issue":"3","key":"pone.0348598.ref002","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/oncolo\/oyab058","article-title":"Treatment patterns, health care resource utilization, and cost in patients with myelofibrosis in the United States","volume":"27","author":"R Copher","year":"2022","journal-title":"Oncologist"},{"key":"pone.0348598.ref003","unstructured":"Orphanet. Primary myelofibrosis. Available from: https:\/\/www.orpha.net\/en\/disease\/detail\/824. Accessed 2024 August."},{"issue":"1","key":"pone.0348598.ref004","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12185-016-2102-3","article-title":"Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan","volume":"105","author":"K Takenaka","year":"2017","journal-title":"Int J Hematol"},{"issue":"1","key":"pone.0348598.ref005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","article-title":"Momelotinib: an emerging treatment for myelofibrosis patients with anemia","volume":"15","author":"HT Chifotides","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1","key":"pone.0348598.ref006","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the mayo clinic experience","volume":"87","author":"A Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"pone.0348598.ref007","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ajh.21574","article-title":"Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype","volume":"85","author":"A Tefferi","year":"2010","journal-title":"Am J Hematol"},{"issue":"1","key":"pone.0348598.ref008","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1182\/asheducation-2016.1.543","article-title":"Myelofibrosis: to transplant or not to transplant?","volume":"2016","author":"R Devlin","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"pone.0348598.ref009","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"S Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"key":"pone.0348598.ref010","unstructured":"GSK. GSK\u2019s Omjjara (momelotinib) approved in Japan for treatment of myelofibrosis. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-s-omjjara-momelotinib-approved-in-japan-for-treatment-of-myelofibrosis\/"},{"issue":"6","key":"pone.0348598.ref011","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"F Palandri","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"pone.0348598.ref012","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/bjh.19812","article-title":"The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: a prospective real-world study on AIFA monitoring registries","volume":"206","author":"M Breccia","year":"2025","journal-title":"Br J Haematol"},{"key":"pone.0348598.ref013","doi-asserted-by":"crossref","first-page":"906211","DOI":"10.3389\/fphar.2022.906211","article-title":"Optimal indicator of death for using real-world cancer patients\u2019 data from the healthcare system","volume":"13","author":"S-C Jang","year":"2022","journal-title":"Front Pharmacol"},{"key":"pone.0348598.ref014","unstructured":"Novartis. Interim results of the special use survey of Jakavi tablets (myelofibrosis, CINC424A1401). 2023."},{"issue":"9","key":"pone.0348598.ref015","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"S Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0348598.ref016","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"C Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"17","key":"pone.0348598.ref017","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"F Cervantes","year":"2014","journal-title":"Blood"},{"issue":"18","key":"pone.0348598.ref018","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2217\/fon-2021-1358","article-title":"Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review","volume":"18","author":"F Passamonti","year":"2022","journal-title":"Future Oncol"},{"issue":"12","key":"pone.0348598.ref019","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41375-021-01261-x","article-title":"Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study","volume":"35","author":"F Cervantes","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"pone.0348598.ref020","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35801","article-title":"Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI)","volume":"131","author":"M Breccia","year":"2025","journal-title":"Cancer"},{"issue":"12","key":"pone.0348598.ref021","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2016.151449","article-title":"The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies","volume":"101","author":"V Gupta","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"pone.0348598.ref022","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2010.031831","article-title":"Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS","volume":"96","author":"C Elena","year":"2011","journal-title":"Haematologica"},{"key":"pone.0348598.ref023","unstructured":"Medical Data Vision. Available from: https:\/\/en.mdv.co.jp\/ebm\/about-mdv-database\/"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0348598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:12:19Z","timestamp":1778281939000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0348598"}},"subtitle":[],"editor":[{"given":"Daniel","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0348598","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]}}}